Medtronic plc, an Ireland-based global healthcare technology company with a market capitalization of approximately $105.4 billion, develops and manufactures medical devices, software, and AI-powered solutions addressing more than 70 medical conditions. The company’s product portfolio spans cardiovascular, neuroscience, diabetes, surgical, and other therapeutic areas.
The company was scheduled to report first-quarter fiscal year 2027 earnings before market open on September 1, 2026. Analysts anticipated diluted earnings per share of $1.38, representing a 9.5% increase from $1.26 in the comparable prior-year quarter. MDT has surpassed Wall Street’s EPS estimates in each of the preceding four quarters.
For full-year fiscal 2027, analyst consensus projected EPS of $5.94, up 7.4% from $5.53 in fiscal 2026. Forward projections indicated additional growth, with fiscal 2028 EPS expected to reach $6.38, representing another 7.4% increase.
MDT’s stock performance over the preceding 52 weeks showed a decline of 10.7%, underperforming both the S&P 500 Index, which returned 18.9%, and the State Street Technology Select Sector SPDR ETF, which climbed 19.4%. On July 21, 2026, Medtronic announced its AI-native Touch Surgery Aide platform, developed using NVIDIA infrastructure, to provide real-time decision support during surgical procedures. The company also received FDA clearance for Instrument Exit Point, its first real-time AI application for the Hugo robotic surgery system.
Analysts maintained a fairly positive outlook on Medtronic stock, with a consensus “Moderate Buy” rating. Among 29 analysts covering the stock, 14 issued “Strong Buy” ratings, two provided “Moderate Buy” ratings, and 13 recommended “Hold.” The average price target of $95.92 indicated potential upside of 17.1% from prevailing share prices.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI